Altered glutamate uptake in peripheral tissues from Down syndrome patients
- PMID: 12759167
- DOI: 10.1016/s0304-3940(03)00260-x
Altered glutamate uptake in peripheral tissues from Down syndrome patients
Abstract
Overexpression of APP and SOD induces beta-amyloid deposition and oxidative stress in Down syndrome (DS) patients. Both phenomena may impair glutamate transport and decreased glutamate uptake sites have been demonstrated in patient brains at autopsy. Since alterations of APP metabolism and oxidative damage are systemic, we investigated glutamate uptake in platelets and fibroblasts from DS patients to explore whether abnormalities in this process are inherent properties of DS cells and not secondary to neurodegeneration. Glutamate uptake was significantly decreased in platelets (P<0.005 vs. control) and fibroblasts (P<0.001 vs. control) from DS patients, particularly in those with free trisomy and with mitochondrial point mutations. Systemic impairment of glutamate uptake in DS is suggested, probably related to APP overexpression and mitochondrial dysfunction. Such mechanisms may contribute to neurodegeneration and dementia development in these patients.
Similar articles
-
Knockdown of amyloid precursor protein normalizes cholinergic function in a cell line derived from the cerebral cortex of a trisomy 16 mouse: An animal model of down syndrome.J Neurosci Res. 2006 Nov 1;84(6):1303-10. doi: 10.1002/jnr.21035. J Neurosci Res. 2006. PMID: 16941497
-
Endosomal abnormalities related to amyloid precursor protein in cholesterol treated cerebral cortex neuronal cells derived from trisomy 16 mice, an animal model of Down syndrome.Neurosci Lett. 2007 Aug 16;423(2):172-7. doi: 10.1016/j.neulet.2007.06.054. Epub 2007 Aug 3. Neurosci Lett. 2007. PMID: 17706358
-
Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation.Neurology. 1996 Oct;47(4):1069-75. doi: 10.1212/wnl.47.4.1069. Neurology. 1996. PMID: 8857747
-
HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.Free Radic Biol Med. 2017 Oct;111:262-269. doi: 10.1016/j.freeradbiomed.2016.10.508. Epub 2016 Nov 10. Free Radic Biol Med. 2017. PMID: 27838436 Free PMC article. Review.
-
Oxidative stress and mitochondrial dysfunction in Down syndrome.Adv Exp Med Biol. 2012;724:291-9. doi: 10.1007/978-1-4614-0653-2_22. Adv Exp Med Biol. 2012. PMID: 22411251 Review.
Cited by
-
Cellular changes underlying hyperoxia-induced delay of white matter development.J Neurosci. 2011 Mar 16;31(11):4327-44. doi: 10.1523/JNEUROSCI.3942-10.2011. J Neurosci. 2011. PMID: 21411673 Free PMC article.
-
Rethinking Intellectual Disability from Neuro- to Astro-Pathology.Int J Mol Sci. 2020 Nov 27;21(23):9039. doi: 10.3390/ijms21239039. Int J Mol Sci. 2020. PMID: 33261169 Free PMC article. Review.
-
Current insights and prospects for the pathogenesis and treatment of clinical manifestations associated with Down syndrome through neurotransmitter, inflammatory, and oxidative stress pathways.Front Pharmacol. 2025 Apr 28;16:1592277. doi: 10.3389/fphar.2025.1592277. eCollection 2025. Front Pharmacol. 2025. PMID: 40356974 Free PMC article. Review.
-
Application of the amniotic fluid metabolome to the study of fetal malformations, using Down syndrome as a specific model.Mol Med Rep. 2017 Nov;16(5):7405-7415. doi: 10.3892/mmr.2017.7507. Epub 2017 Sep 18. Mol Med Rep. 2017. PMID: 28944830 Free PMC article.
-
Plasma amino acids and neopterin in healthy persons with Down's syndrome.J Neural Transm (Vienna). 2007;114(8):1041-5. doi: 10.1007/s00702-007-0656-1. Epub 2007 Mar 31. J Neural Transm (Vienna). 2007. PMID: 17401539 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical